SLXN

Silexion Therapeutics Ltd. (SLXN) SWOT Analysis Analysis (2026)

Invetso Score: 4.9/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 5.8 (Moderate)

ROIC of 6.3% indicates SLXN is generating acceptable capital returns, but this remains below stronger peer franchises with consistently higher reinvestment efficiency.

Net debt to EBITDA of 0.06x suggests balance-sheet leverage is minimal, giving SLXN more financial flexibility than more indebted peers in the same coverage set.

The reported cash conversion cycle is deeply negative, implying working-capital efficiency that can support liquidity and operating resilience versus peers with longer cash cycles.

Weaknesses

Score:

Debt to equity of 32.0x signals a highly levered capital structure, which is structurally weaker than peers with more conservative equity funding.

Current and quick ratios of 0.94x indicate near-term liquidity is below the 1.0x threshold, leaving SLXN less cushioned than peers with stronger working-capital buffers.

Missing operating and gross margin disclosure limits visibility into core profitability, making SLXN harder to benchmark against peers on durable margin quality.

Opportunities

Score:

If SLXN sustains its working-capital efficiency, it can convert operating activity into cash more effectively than peers with slower inventory and receivables turnover.

Low net debt relative to EBITDA creates room to fund growth or absorb volatility more easily than more leveraged peers, supporting strategic optionality.

Improving disclosure and demonstrating stable margin performance would help SLXN narrow the information gap versus peers and strengthen investor comparability.

Threats

Score:

High debt-to-equity leaves SLXN more exposed than peers to refinancing pressure or equity dilution if operating conditions weaken.

Liquidity ratios below 1.0x increase vulnerability versus peers with stronger short-term coverage, especially if cash needs rise unexpectedly.

Without visible margin data, SLXN faces a relative credibility gap versus peers that report stronger profitability, which can weigh on market positioning.

Overall Score

Score:

SLXN shows some balance-sheet flexibility and working-capital efficiency, but its high leverage and sub-1.0x liquidity keep structural positioning only moderate versus peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Silexion Therapeutics Ltd.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →

Invetso is not affiliated with or regulated by the U.S. Securities and Exchange Commission (SEC), the Financial Industry Regulatory Authority (FINRA), or any other financial regulatory authority. The analyses, scores and all the information provided by Invetso are strictly for informational purposes only and do not constitute financial advice, recommendations, or an offer to buy or sell any securities. Invetso is not a registered financial advisor, broker-dealer, or investment advisor, and it does not provide personalized investment, legal, or tax advice. The content provided on this website is not intended to serve as a substitute for professional advice. Users should conduct their own research and consult with a qualified financial advisor before making any investment decisions. All analysis, data, and information presented on this site are based on publicly available information and should be used at the user’s own risk. Invetso does not guarantee the accuracy, completeness, or timeliness of any information or data provided, nor does it endorse any specific securities, companies, or strategies. Any reliance you place on such information is strictly at your own risk. While we strive to provide accurate and up-to-date information, Invetso makes no warranties or representations regarding the completeness, accuracy, or reliability of any analyses or data on our platform, and any such information is subject to the terms and conditions of the Invetso Terms of Service. Our analyses are generated using AI technologies and AI-generated content may contain errors or inaccuracies. Use the information at your own risk. Our platform may contain links to third-party websites, for which we are not responsible for the content or accuracy of information. Invetso shall not be liable for any loss or damage arising from the use of our services. By using this website, you agree that Invetso is not responsible for any losses, damages, or financial outcomes that may result from your use of the information, tools, or resources provided. We recommend consulting with a licensed financial professional before making any investment decisions.

For more details, please refer to our Terms of Service and Privacy Policy.